Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism.
Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs.
Bucket Robotics builds modular autonomous mobile robots for warehouse and industrial environments, designed for rapid deployment without requiring fixed infrastructure or facility modifications.
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse automation systems that require significant facility modifications, fixed conveyors, and multi-month installation projects, Bucket Robotics' AMRs navigate dynamically using onboard sensors and AI, allowing deployment in existing facilities without permanent infrastructure changes.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.